These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32595092)

  • 1. Survival analysis of patients with prostate cancer and unfavorable risk factors treated with radical prostatectomy and salvage radiotherapy after biochemical recurrence and persistence.
    Barbas Bernardos G; Herranz Amo F; González San Segundo C; Caño Velasco J; Subirá Ríos D; Moralejo Gárate M; Mayor de Castro J; Aragón Chamizo J; Hernández Fernández C
    Actas Urol Esp (Engl Ed); 2020 Dec; 44(10):701-707. PubMed ID: 32595092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncological control in high-risk prostate cancer after radical prostatectomy and salvage radiotherapy compared to radiotherapy plus primary hormone therapy.
    Caño-Velasco J; Herranz-Amo F; Barbas-Bernardos G; Polanco-Pujol L; Verdú-Tartajo F; Lledó-García E; Hernández-Fernández C
    Actas Urol Esp (Engl Ed); 2019 May; 43(4):190-197. PubMed ID: 30878158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
    Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J
    Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy.
    Ying J; Wang CJ; Yan J; Liauw SL; Straka C; Pistenmaa D; Xie XJ; Lotan Y; Roehrborn C; Kim DN
    Am J Clin Oncol; 2017 Dec; 40(6):612-620. PubMed ID: 26165416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Lee EK; Mui WH; Chan AW; Tung Y; Wong FC
    Hong Kong Med J; 2018 Jun; 24(3):218-225. PubMed ID: 29807949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival.
    Bartkowiak D; Thamm R; Bottke D; Siegmann A; Böhmer D; Budach V; Wiegel T
    Acta Oncol; 2018 Mar; 57(3):362-367. PubMed ID: 28816074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of the site of positive surgical margin in salvage external beam radiation therapy for biochemical recurrence of prostate cancer after radical prostatectomy.
    Kashihara T; Nakamura S; Wakita A; Okamoto H; Inaba K; Umezawa R; Shima S; Tsuchida K; Kobayashi K; Takahashi K; Murakami N; Ito Y; Igaki H; Fujimoto H; Uno T; Itami J
    Cancer Med; 2018 May; 7(5):1723-1730. PubMed ID: 29573193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage radiotherapy for biochemical recurrence after radical prostatectomy: does the outcome depend on the prostate cancer characteristics?
    Viani GA; Hamamura AC; Correa AC; de Arruda FT
    Int Braz J Urol; 2019; 45(2):237-245. PubMed ID: 30676298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
    Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
    Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy : Long-term follow-up of a single-center survey.
    Lohm G; Lütcke J; Jamil B; Höcht S; Neumann K; Hinkelbein W; Wiegel T; Bottke D
    Strahlenther Onkol; 2014 Aug; 190(8):727-31. PubMed ID: 24577132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy.
    Geinitz H; Riegel MG; Thamm R; Astner ST; Lewerenz C; Zimmermann F; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1930-7. PubMed ID: 21514736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
    Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival.
    Bartkowiak D; Bottke D; Thamm R; Siegmann A; Hinkelbein W; Wiegel T
    Radiother Oncol; 2016 Jan; 118(1):131-5. PubMed ID: 26653358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of salvage radiotherapy for PSA-recurrent prostate cancer: validation of the Stephenson nomogram.
    Hugen CM; Polcari AJ; Quek ML; Garza RP; Fitzgerald MP; Flanigan RC
    World J Urol; 2010 Dec; 28(6):741-4. PubMed ID: 20449749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative adjuvant and very early salvage radiotherapy after prostatectomy in high-risk prostate cancer patients can improve specific and overall survival.
    Casas F; Valduvieco I; Oses G; Izquierdo L; Archila I; Costa M; Cortes KS; Barreto T; Ferrer F
    Clin Transl Oncol; 2019 Mar; 21(3):355-362. PubMed ID: 30128953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer.
    Bartkowiak D; Thamm R; Siegmann A; Böhmer D; Budach V; Wiegel T
    Radiother Oncol; 2021 Jan; 154():255-259. PubMed ID: 32920006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of biochemical recurrence after radical prostatectomy. New tool for selecting candidates for adjuvant radiation therapy.
    Herranz-Amo F; Molina-Escudero R; Ogaya-Pinies G; Ramírez-Martín D; Verdú-Tartajo F; Hernández-Fernández C
    Actas Urol Esp; 2016 Mar; 40(2):82-7. PubMed ID: 26424411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.